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INTRODUCTION 
Although the life expectancy of patients 
with Human Immunodeficiency Virus (HIV) 
has largely improved with introduction of 
Antiviral Therapy (ART) and Highly Active 
Antiviral Therapy (HAART), HIV and 
Acquired Immunodeficiency Disease (AIDS) 
continue to be a major health problem 
threatening people around the world.
1-3
 
Current statistics indicates that until 2013, 
there were 35 million HIV-positive 
individuals around the world among whom, 
31.8 million were adults and 3.2 million 
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ABSTRACT 
Background and aims: The pandemic of AIDS is a global emergency and one of the 
biggest challenges in social and individual life. This study aimed to evaluate the survival 
time of HIV patients and its effective factors. 
Methods: This historical cohort study was conducted on the individuals infected with 
HIV in Fars province, south of Iran, during 2006 to 2013. The study data were obtained 
from information documented in the patients’ records. For statistical analysis, at first, 
Kaplan-Meier survival analysis was used as univariate method and then, time varying 
Cox regression model was applied as multiple analyses. 
Results: The findings of the present study implied that some variables could play the role 
of risk factors in HIV patients, and shorten the patients’ life span e.g. older age, female 
gender, unemployment, delay in HIV diagnosis, drug injection, and higher Hemoglobin 
(HGB) levels. 
Conclusion: Many factors affect HIV patients’ survival time. Some of these factors, such 
as gender and genetic factors, are irreversible. However, some others, including drug 
injection, are preventable. This implies that in order to slow down the speed of HIV 
conversion to AIDS and delay the occurrence of death, special attention must be paid to 
these factors and changing the patients’ conditions accordingly. 
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were children below 5 years of age. In 
addition, global statistics showed that  
2.1 million people were newly infected with 
HIV in 2013.
4
 Based on Iran’s statistics in 
2013, the prevalence of HIV was 0.2% in 
the patients between 15 and 49 years old. It 
was also estimated that there were 86,000 
HIV-positive patients in the country.
5
 The 
importance of this issue is manifested more 
by considering the fact that up to now, no 
definitive treatment has been found for 
AIDS and these patients died by various 
factors, such as Tuberculosis (TB), hepatitis 
B and C, liver diseases, non-AIDS-related 
malignancies, and problems related to 
HAART such as heart diseases.
2,6,7
 In 2013, 
one and half million people worldwide and 
4300 ones in Iran died due to AIDS.
4,5
 
Roshanayee and colleagues conducted a 
study entitled “survival rates of human 
immunodeficiency virus and tuberculosis 
co-infected patients” in Iran, examining  
807 patients who were only infected  
with TB and 21 patients who were 
simultaneously diagnosed with TB and HIV. 
In that study, Kaplan-Meier method and Log 
Rank test were used for data analysis. Their 
study results showed that co-infection of TB 
and HIV significantly increased death  
rate. Accordingly, the rate of death was  
20.7 folds (Hazard Ratio (HR)= 8.1 to 53) 
higher in the patients infected with both HIV 
and TB compared to those who were only 
infected with TB. Moreover, marital status 
was introduced as a risk factor for survival 
of HIV patients and the death HR was  
2.1 folds higher in married individuals 
compared to single ones.
8
 In another study 
conducted by Mirzaee and colleagues on 
585 HIV-positive patients in Hamadan, Iran, 
the information registered in the patients’ 
health records was used. In that study, Cox 
proportional hazard model was used for 
survival analysis. The results indicated that 
using HAART could act as a protective 
factor, because death HR was 4.1 folds 
higher in the patients who did not receive 
HAART compared to those who used this 
treatment. On the other hand, TB and HIV 
co-infection was one of the most important 
risk factors for the patients’ survival.9 
Antiretroviral Therapy Cohort Collaboration 
(ATCC) also carried out a research on 
39272 HIV-positive patients who had 
participated in 13 retrospective cohort 
studies. The results showed that more than 
85% (1597) of the HIV patients’ deaths 
could be attributed to the specific factors.  
So as to 49.5%, 11.8%, 8.2%, 7.7%, 7%,  
and 6.5% of deaths were related to AIDS, 
malignancies uncorrelated to AIDS, 
infections uncorrelated to AIDS, violence or 
drug abuse, liver diseases, and heart 
diseases, respectively.
6
 
Overall, the pandemic of AIDS is a 
global emergency and one of the biggest 
challenges in social and individual life.
10-12
 
Furthermore, it forms and undermines social 
and economic growth around the world. 
Although, global statistics of the disease 
have decreased especially in developed 
countries, unfortunately, this trend is 
increasing in Iran.
13,14
 Therefore, the present 
study aims to evaluate HIV patients’ 
survival time and its effective factors. In this 
way, application of appropriate educational 
and interventional proceedings could 
prolong HIV patients’ lifetime. 
 
METHODS 
This historical cohort study was 
conducted on individuals infected with HIV 
in Fars province, south of Iran, during  
2006-2013. The study data were collected 
using the information documented in the 
patients’ records. These records have been 
archived by Behavioral Disease Consulting 
Center of Shiraz University of Medical 
Sciences, Shiraz, Iran. 
The information in the patients’ records 
consisted of three types of variables: 1. The 
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dependent variable; i.e., survival time;  
2. Repeatedly measured independent 
variables, such as White Blood Cells (WBC) 
count, Total Leukocyte Count (TLC), Platelet 
(PLT) count, Hematocrit (HCT) levels, 
Hemoglobin (HGB) level, and Erythrocyte 
Sedimentation Rate (ESR); 3. Other variables 
that were covariates, including gender, 
education level, marital status, occupation, 
addiction status, HIV transmission way, joint 
injection, Hepatitis B Virus (HBV), Hepatitis 
C Virus (HCV), prophylaxis for TB, HAART, 
HIV level at diagnosis, CD4 cell count and 
age. Method of stratification of the categorical 
variables has been presented in Table 1 in the 
“Results” section. 
In this study, the samples were selected 
through census method. In doing so, all the 
HIV-infected individuals identified during 
the aforementioned years who had three 
measurements of CBC (n=1052) were 
recruited into the study. HIV infection was 
confirmed by two ELISA positive test 
results and a Western blot test result. These 
tests were performed for the patients 
voluntarily or, in some cases, because of 
requirements, such as marriage or 
employment. After confirmation of HIV 
infection through these tests, the patients 
were introduced from the laboratory to the 
health center located at their place of 
residence, so that Behavioral Disease 
Consulting Center could cover the patients 
and perform the necessary periodical testing 
and follow-up. In this study, 1052 out of the 
1565 HIV-positive patients with three CD4 
measurements in their records were selected 
for statistical analysis. 
In this study, the desired outcome was 
the HIV patients’ survival time from 
diagnosis to death. Repeatedly measured 
independent variables were measured at 
baseline and six months and one year later. 
Although the missing values of this study 
were low (less than 5%), multiple 
imputation method (regression) with 5 times 
integration was employed for estimation of 
missing values. At first, the relationship 
between the above-mentioned factors  
and survival time was evaluated by  
Kaplan-Meier survival analysis as the 
univariate method. It should be mentioned 
that Log Rang test was utilized for 
determining the significance level of 
Kaplan-Meier results. In univariate analysis, 
the factors with P<0.2 were considered to be 
significant and were entered into multiple 
analysis. For multiple modeling, time-
varying Cox regression model was used. In 
multiple modeling, the factors with P<0.05 
were considered to be significant. All these 
analyses were performed using the SPSS 
statistical software, version 21 and Stata 
software, version 11. 
 
RESULTS 
This study was conducted on 1052 HIV 
positive persons that 286 of them died and 
their median survival time was equaled to  
5 years. Also, whose descriptive statistics 
according to the categorical variables have 
been presented as number (n) and 
percentage (%) in the upper part of Table 1. 
The method of stratification of the 
categorical variables has also been shown in 
Table 1. Besides, number (n) and mean of 
the patients in terms of continuous variables 
have been displayed in the lower part of 
Table 1. 
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Table 1: Characteristic of the patients based on categorical and continuous variables 
Categorical Variables n % 
Gender Male 822 78.1 
Female 230 21.9 
Education level Illiterate 81 7.7 
Elementary school 329 31.3 
Middle school 396 37.6 
High school 208 19.8 
Academic education 38 3.6 
Marital status Divorced 152 14.4 
Married 502 47.7 
Single 382 36.3 
Temporary marriage 16 1.5 
Occupation Unemployed 462 43.9 
Employed 590 56.1 
TB prophylaxis No 284 27.0 
Yes 768 73.0 
HAART No 441 41.9 
Yes 611 58.1 
HCV result Positive 749 71.2 
Negative 303 28.8 
HBS result Positive 830 78.9 
Negative 222 21.1 
HIV level Asymptomatic 776 73.8 
Advanced clinical stage 276 26.2 
Addiction status None 231 22.0 
Quitted 198 18.8 
Using 623 59.2 
Transmission way Drug injection 701 66.6 
Sex 320 30.4 
Transfusion 31 2.9 
Joint injection Yes 749 71.2 
No 303 28.8 
Continues variables n Mean(SD) 
HIV duration 1052 5.54(1.88) 
Age 1052 35.28(42.90) 
Baseline CD4 count 1052 342.13(192.98) 
WBC 1052 4875.46(1601) 
TLC 1052 1684.51(629) 
PLT 1052 200.81(64) 
HCT 1052 36.80(6.37) 
HGB 1052 12.46(1.8) 
ESR 1052 43.16(20) 
 
The univariate analysis findings of 
Kaplan-Meier survival analysis showed that 
age, gender, marital status, occupation, TB 
prophylaxis, HAART, HCV, HIV level, 
addiction status, drug injection, total CD4 
count, WBC count, TLC, PLT count, HCT 
level, HGB level, and ESR were 
significantly (their Log Rank test P<0.2) 
associated with the patients’survival time 
(Table 2). It should be mentioned that this 
table only shows the variables that were 
related to survival time, but does not display 
the direction and magnitude of the 
associations. 
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Table 2: Univarite survival analysis results using Kaplan-Meier and Log Rank methods 
Variables Mean of survival time (year) Log Rank (Mantel-Cox) 
Estimate 95% confidence interval Chi-square df Sig 
Lower Upper 
Age Year 5.58 5.44 5.72 3.24  0.07 
Gender Male 5.61 5.44 5.78 3.80 1 0.05 
Female 5.47 5.20 5.74 
Education level Illiterate 5.42 4.92 5.91 1.12 4 0.28 
Elementary school 5.81 5.54 6.07 
Middle school 5.47 5.25 5.70 
High school 5.66 5.34 5.99 
Academic 5.08 4.41 5.75 
Marital status Divorced 5.48 5.11 5.85 2.93 3 0.08 
Married 5.50 5.29 5.70 
Single 5.68 5.45 5.91 
Temporarily married 5.75 5.40 8.09 
Occupation Unemployed 5.72 5.50 5.94 10.12 1 0.00 
Employed 5.45 5.26 5.63 
TB prophylaxis No 5.69 5.41 5.97 1.67 1 0.19 
Yes 5.54 5.37 5.70 
HAART No 5.45 5.27 5.64 2.43 1 0.12 
Yes 5.78 5.56 6.00 
HCV Positive 5.70 5.53 5.87 3.60 1 0.05 
Negative 5.31 5.05 5.58 
HBV Positive 5.50 5.18 5.81 0.14 1 0.7 
Negative 5.60 5.44 5.76 
HIV level Advanced 5.48 5.31 5.64 2.27 1 0.13 
Asymptomatic 5.89 5.62 6.16 
Addiction status None 5.52 5.24 5.81 1.66 1 0.19 
Quitted 5.46 5.13 5.80 
Using 5.64 5.45 5.83 
Transmission way Drug injection 5.61 5.43 5.79 0.61 1 0.43 
Sex 5.47 5.23 5.72 
Transfusion 6.16 5.23 7.09 
Joint injection No 5.66 5.48 5.83 7.47 1 0.00 
Yes 5.39 5.14 5.63 
Baseline CD4 ≤ 100 5.47 4.86 6.07 0.14 1 0.70 
> 100 5.59 5.44 5.74 
Total CD4 ≤ 100 5.51 5.36 5.66 3.84 1 0.05 
> 100 6.05 5.69 6.42 
WBC mg/dL 5.58 5.44 5.72 549.491 238 0.00 
TLC mg/dL 5.58 5.44 5.72 445.94 206 0.00 
PLT mg/dL 5.58 5.44 5.72 816.23 382 0.00 
HCT mg/dL 5.58 5.44 5.72 429.13 192 0.00 
HGB mg/dL 5.58 5.44 5.72 412.01 173 0.00 
ESR mg/dL 5.58 5.44 5.72 1572.47 627 0.00 
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Time varying Cox regression analysis 
outputs as multiple analysis indicated that 
age, occupation and HIV level at diagnosis 
significantly affected the patients’ mean 
survival time (P≤0.05). Among these 
variables, age was negatively associated with 
the HIV patients’ survival time, because it’s 
HR was more than one. Accordingly, 
increase in the patients’ age resulted in a 
decrease in their survival time. The results of 
time varying Cox regression also showed that 
jobless patients and those with advanced 
stage of HIV at diagnosis had lower survival 
time compared to the patients who did not 
have these characteristics. Among the 
variables that were measured repeatedly, only 
HGB level had a significant negative effect 
on the patients’ survival (Table 3). 
 
Table 3: The results of multivariate survival analysis using time varying Cox (TVC) regression 
Variables Hazard ratio SE Z P>│Z│ 95% Conf. interval 
Age 0.44 0.16 -2.17 0.03 0.21-0.92 
Gender 0.83 0.19 -0.97 0.33 0.47-1.20 
Education level Illiterate 1    0.96-1.02 
Elementary 0.99 0.03 1.68 0.65 1.00-1.05 
Middle 1.03 0.04 1.15 0.17 0.98-1.03 
High 1.01 0.02 1.36 0.27 0.96-1.14 
Academic 1.05 0.04 1.22 0.22  
Marital status Divorced 1     
Married 0.98 0.05 -1.07 0.23 0.95-1.07 
Single 0.96 0.03 -1.05 0.19 0.94-1.04 
Temporarily 0.94 0.04 -1.04 0.29 0.91-1.01 
Occupation 1.25 0.10 2.65 <0.001 0.85-1.04 
TB prophylaxis 1.16 0.11 1.65 0.09 1.06-1.49 
HAART 1.09 0.10 0.93 0.35 0.97-1.20 
HCV 1.16 0.13 1.31 0.19 0.90-1.31 
HBS 1.09 0.10 0.93 0.35 0.92-1.45 
HIV level 0.78 0.08 -2.11 0.03 0.90-1.33 
Addiction status 0.91 0.07 -1.19 0.23 0.63-0.98 
Transmission way 0.84 0.11 -1.29 0.19 0.77-1.06 
Joint injection 1.23 0.17 1.50 0.13 0.64-1.09 
TVC* CD4 1.01 0.02 0.89 0.37 0.93-1.62 
WBC 0.99 4.04 -0.98 0.32 0.97-1.06 
PLT 1.00 0.00 0.11 0.90 0.99-1.00 
HCT 0.99 0.00 -0.36 0.72 0.99-1.00 
HGB 1.20 0.01 3.55 0.04 0.99-1.00 
ESR 1.00 0.00 1.12 0.26 1.19-1.20 
*: TVC= Time Varying Cox. 
 
DISCUSSION 
This study aimed to determine the 
effective factors in HIV patients’ survival 
time. The study findings implied that  
some variables were risk factors in HIV 
patients, accelerated disease progression, 
and shortened the patients’ life span. These 
variables included older age, female gender, 
unemployment, delay in HIV diagnosis, 
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drug injection, and higher HGB levels. In 
contrast, some factors, including middle age 
(20-40 years), receiving HAART, and 
higher values of some CBC factors such as 
TLC and HCT,could slow down HIV 
progression and prolong the patients’ 
lifetime. 
The findings of the present study 
displayed that older ages affected 
development of AIDS symptoms and 
occurrence of early death. Several studies 
have also shown that the higher the HIV 
patients’ age, the more quickly their 
infection will be converted to AIDS.
15-17
 In 
one study, for example, the median time 
from serocon version to AIDS without 
therapy was 15 years for 16-24-year-old 
patients, but 6 years for those who were  
35 years old or above.
18
 Similarly, another 
study indicated that in the absence of 
HAART, faster overall progression to AIDS 
occurred with increasing age, especially 
after the age of 40 years. Also, the speed of 
disease progression was higher among 
younger children, especially newborn  
HIV-positive patients. On the other hand, 
the slowest rate of progression was seen in 
teenager patients. This might be justified by 
the fact that with increasing age, CD4 cell 
replacement power is decreased because 
fewer and naïve CD4 cells are generated by 
the thymus gland. An alternative explanation 
is that with increasing age, there are lower 
levels of chemokines to intervene with 
HIV’s ability to infect CD4 T-cells.15,19 
According to the findings of our study, 
female gender was a risk factor for HIV 
patients’ survival time. Similarly, Hongbo 
Jiang et al. conducted a cohort study in 
China and showed that a larger number of 
women compared to men entered AIDS after 
1 year (23% vs. 17%) and 3 years (45% vs. 
35%).
20
 Moreover, other studies showed that 
the mean of HIV-RNA varied between men 
and women for given CD4 count strata and 
was higher in women compared to men. 
Moreover, the mean of survival time was 
less in women compared to men.
21,22
 The 
dominant idea is that gender itself does not 
affect HIV progression, morbidity, or 
mortality, but some differences can be 
attributed to the effect of confounders, such 
as poverty and poor access to medical care. 
Furthermore, gender via other factors, such 
as genetic, hormonal, and psychological 
variables, makes differences between men 
and women. Such studies indicated that host 
genetic factors, e.g. chemokine receptors 
CXCR4 and CCR5 and their natural ligands, 
and immune response play important roles 
in progression of HIV to AIDS or death.
23,24
 
Many studies have also identified a role for 
HLA genotype for HIV outcomes.
25
 Rapid 
progression to AIDS has been associated 
with HLA alleles A24, B35, B37, B56, 
B58S, and A1-B8-DR3.
26
 In contrast, alleles 
B57, B27, B14, and C8 have been associated 
with long-term non-progression.
27
 
The results of the present study indicated 
a negative association between HGB level 
and HIV patients’ survival time. Slama  
and colleagues conducted a study on 1500  
HIV-uninfected and 1357 HIV-infected men 
with a median of 11 visits for each participant 
for over 13 years. At Fasting Blood Sugar 
(FBS) level of 125 mg/dL, the median 
HGBA1c among the HIV-infected men  
was 0.21% lower than that among the  
HIV-uninfected ones.
28
 In another study 
accomplished by Alavi et al. in Iran, a strong 
correlation was observed between CD4  
count and TLC (r=0.645, P=0.001), but no 
correlation was seen between CD4 count, and 
HGB and HCT levels (r=0.451, P=0.056 and 
r=0.375, P=0.816, respectively). That study 
showed that TLC was a suitable surrogate 
marker for CD4 count. However, HGB and 
HCT levels were of limited value in 
predicting CD4 count and should not be 
substituted for CD4counts.
29
 These findings 
were not consistent with those obtained in 
Slama’s study and the present one. This 
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difference might result from the small sample 
size of Alavi’s study (n=100) and the fact 
that a few variables were entered into that 
study, which might have confounded the 
findings. In addition, they only used Pearson 
correlation coefficient method for data 
analysis and did not use multiple analysis for 
adjustment of confounders. 
According to the findings of the current 
study, unemployment was a risk factor for 
progression of HIV to death. In general, 
patients who have a job have better nutrition 
compared to jobless ones. They also use 
health services more that can improve their 
health. Studies have demonstrated that 
micronutrient supplements might be benefit 
in some patients with HIV infection.
25-27
 A 
randomized trial on 1078 pregnant women 
in Tanzania also showed that the women 
who received a multivitamin supplement 
(vitamins B, C, and E) had delayed 
progression of HIV compared to those 
receiving the placebo.
25
 
The results of our study revealed that 
HIV infection through injection was a  
risk factor for accelerating the disease 
progression and shortening of survival time. 
Similarly, some studies have demonstrated 
that the patients who acquired their HIV 
infection through drug injection had higher 
death rates compared to those acquiring their 
infection via sex.
30,31
 Moreover, the results 
of a study conducted on more than  
22,000 patients from Europe and North 
America indicated that AIDS event rates 
decreased more rapidly in Men who have 
Sex with Men (MSM) in comparison to 
injection drug users.
31
 Besides, the findings 
of a prospective, longitudinal study 
conducted on a cohort of 222 HIV-infected 
drug users in Camillus House, Miami 
showed that crack-cocaine users were  
2.14 times [95% Confidence Interval (CI): 
1.08 to 4.25, P=0.029] more likely to present 
a decline of CD4 to ≤ 200 cells/mL, 
independent of antiretroviral use.
32
 Injection 
drug use could have an effect on HIV 
progression because drugs, such as opioids, 
may increase HIV replication in vitro.
33,34
 
Furthermore, drug use may negatively affect 
medication adherence and use of medical 
care.
35
 Intoxicating effects of many drugs 
can change individuals’ judgment and 
inhibition and cause them to take part in 
capricious and unsecure behaviors, which 
eventually worsen the patients’ conditions. 
The current study results indicated that 
receiving HAART and TB prophylaxis 
could slacken the speed of HIV conversion 
to AIDS and prolong patients’ lifetime. In 
the same line, Pepe and his colleagues 
conducted a study on HIV patients and 
reported that the incidence of TB and  
HIV progress were lower in Isoniazid  
pill recipients than in the patients who 
received B6 vitamin alone (2.2 vs. 7.5 per 
100 person-years).
36
 In addition, in the study 
implemented by Peter et al. for determining 
the effect of different types of treatment on 
prevention of HIV, Kaplan-Meier estimates 
of progression rates to AIDS at 18 months 
were 13.6% (mono therapy), 4.7% (RTI 
combination therapy), and 3.9% (HAART).
37
 
Coinfection with other pathogens may 
influence the rate of HIV progression. For 
instance, coinfection with TB accelerates 
HIV-associated immunodeficiency and 
increases the levels of viremia. Therefore, it 
is evident that TB prophylaxis could delay 
HIV progression to death.
38
 
Of course, there was some limitations in 
this research. Since many factors affect HIV 
progression and many of these factors  
have partial associations with each other 
(e.g. genetic factors have correlations with 
gender, sensitivity, and progression of HIV), 
not having any information about such 
variables (similar to this study) might induce 
confounding effects. As a result, cofounding 
could have aggravated, mitigated, or masked 
the observed correlations because its effect 
was not adjusted. Another limitation of the 
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current study was making use of recorded 
data. Since these data were collected for 
patients’ follow-up and surveillance, they 
might not be of high quality. Finally, if the 
patients referred to the clinics in early stage 
of the disease, their morbidity was 
diagnosed in the first step. However, some 
patients might have referred to laboratory at 
advanced stages of the disease. If so, using 
HIV duration or baseline CD4 count might 
not give correct or appropriate results. 
 
CONCLUSION 
Many factors affect HIV patients’ 
survival time. Some of these factors, such as 
gender and genetic factors, are irreversible. 
However, some others, including drug 
injection are preventable. This implies that in 
order to slow down the speed of HIV 
conversion to AIDS and delay the occurrence 
of death, special attention should be paid to 
these factors and changing the patients’ 
conditions accordingly. 
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